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Abstract
Persistence of transcriptionally silent replication competent HIV-1 is a major barrier to
clearance of the virus from patients; current combinatorial antiretroviral therapies are
successful in abrogating active viral replication, but are unable to eradicate latent HIV-1.
A “shock and kill” strategy has been proposed as a curative approach in which latent vi‐
rus is activated and infected cells are removed by immune clearance, while new rounds
of infection are prevented by antiretroviral therapy. Much effort has been put toward un‐
derstanding the molecular mechanisms maintaining HIV latency and the nature of reser‐
voirs, to provide novel therapeutic targets. This has led to the development of latency
reversal agents (LRAs), some of which are undergoing clinical trials. Targeting multiple
mechanisms underlying HIV latency via a combination of LRAs is likely to result in more
potent activation of the latent reservoir. Therefore, novel as well as synergistic combina‐
tions of therapeutic molecules are required to accomplish more potent latency reversal.
Keywords: HIV-1 latency, Latency reversal agents (LRAs), Combinatorial antiretroviral
therapy
1. Introduction
Human immunodeficiency virus-1 (HIV-1) is a lentivirus, a subgroup of Retroviridae. Like all
retroviruses, HIV-1 virions consist of an RNA genome with viral proteins encapsulated in a
viral envelope. The viral proteins execute key steps to establish a productive infection by stably
integrating into the host genome. Unlike most retroviruses, HIV-1 can also directly infect
nondividing cells. HIV-1 preferably infects a subset of T-lymphocytes (CD4+ T-cells) that play
a crucial role in the immune response. HIV-1 infection causes exhaustion and ultimately
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depletion of the host immune system, a syndrome termed acquired immuno-deficiency
syndrome (AIDS). HIV-1 came into prominence with the outbreak of the AIDS epidemic in the
1980s. Major steps have been taken toward treating this viral infection. In particular, combi‐
natorial antiretroviral therapy (cART) successfully abrogated HIV-1 replication. Thus, for
compliant patients with access to c-ART, HIV infection has become a chronic rather than a
lethal disease. However, cessation of antiretroviral therapy results in viral rebound in infected
patients, even after years of cART. This is because in a small fraction of infected cells, HIV
persists in a latent but replication-competent state. Latent HIV is unaffected by cART, but
infection can rebound upon cART interruption. Therefore, HIV latency is the main challenge
in developing a curative therapy for HIV.
The quest for an HIV-1 cure involves the development of either a sterilizing or a functional
cure. A sterilizing cure would require complete removal of replication competent viral genetic
material from the infected patient and thus the stable depletion of latently HIV-infected cells.
A functional cure, on the other hand, requires the patient’s immune system to suppress HIV-1
replication life-long in the absence of cART without disease progression, loss of CD4+ T cells
and HIV transmission. The functional cure does not aim to eradicate the virus entirely from
the patient. Both the sterilizing and functional cure strategies are currently the subject of major
research efforts.
2. Clinical picture of HIV
The AIDS epidemic in the 1980s led to the identification of HIV as the causative agent. AIDS
is a condition in which depletion of CD4+ T-cells overtime leads to the loss of the host immune
system’s ability to fight infections and cancers, eventually leading to death. As HIV was
identified as the causative agent, cure efforts focused on disrupting the viral lifecycle. In the
early 1990s, the first antiretroviral therapies – monotherapies – had limited success as they
resulted in rebound of viremia due to the appearance of resistant viral strains. Resistant HIV
required novel therapeutic strategies. Therefore, a combination of anti-retrovirals, targeting
distinct steps of the viral life cycle was developed, so-called combinatorial antiretroviral
therapy (cART). cART has proven to be extremely successful in lowering the amount of viral
RNA in plasma below the limits of detection by standard laboratory techniques. Unfortunately,
the therapy does not eradicate the virus as cessation of medication causes re-emergence of viral
replication [1–3]. Thus, a fraction of the virus escapes the effects of cART. The source for this
recurring viral replication is a small pool of latently infected cells that harbor integrated
proviruses which, while silent, are not recognized by either the immune system nor are they
subject to cART. Moreover, HIV can persist in the presence of cART in certain anatomical sites
if drug penetrance is incomplete.
According to the World Health Organization (WHO), the number of HIV-infected individuals
worldwide in late 2014 was estimated to be approximately 37 million [4]. The vast majority of
infected people live in sub-Saharan Africa, where access to appropriate diagnostic centers and
cART is limited. Estimates put new infections at 5,600 a day in 2014.
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2.1. HIV-1 replication cycle and state-of-the-art antiretroviral therapy
HIV-1, as all viruses, is a parasite of the host cell and hijacks key cellular processes to establish
a productive infection. To produce new virions, the virus goes through a viral replication cycle.
HIV’s replication cycle consists of entering the cell by docking at the cell surface receptor CD4
and co-receptors CCR5/CXCR5 and fusing to the cell, un-packaging of the genome, reverse
transcription of the viral RNA genome into double-stranded DNA, which is the main compo‐
nent of the pre-integration complex, followed by integration of the double-stranded DNA
genome into the host genome, transcription of the provirus, translation of viral proteins, and
ultimately virion biogenesis followed by budding from host cell and maturation. Modern
cART targets most steps in the HIV viral replication cycle (Figure 1). There are currently 28
approved agents for the treatment of HIV infection [5]. They fall into six mechanistic major
classes, which act at different stages in the HIV replication cycle:
1. Fusion inhibitors: enfuvirtide (ENF, T-20), the only currently available fusion inhibitor,
binds to the gp41 receptor site, preventing the fusion of the virus with the target cell.
2. C-C chemokine receptor type 5 (CCR5) antagonists: maraviroc (MVC) is currently the only
available CCR5 antagonist. This drug is an entry inhibitor, specifically blocking the human
chemokine receptor CCR5.
3. Nucleoside (nucleotide) reverse transcriptase inhibitors (NRTIs) block the addition of
nucleosides to the DNA chain during reverse transcription of RNA.
4. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) bind to and inhibit the enzyme
reverse transcriptase (RT), preventing conversion of viral RNA to DNA during infection.
5. Integrase inhibitors (INIs): raltegravir (RAL), elvitegravir (EVG) and dolutegravir (DTG)
are the only currently available drugs in this class. They target the HIV enzyme integrase
(IN) that is required for insertion of viral genetic material into human DNA.
6. Protease inhibitors (PIs) bind to the catalytic site of HIV aspartic protease, blocking the
processing of viral proteins (eg. Saquinavir).
These antivirals comprise the various current cART regimens that are used in the clinic. cART
has proven to be extremely successful in suppressing viral replication in compliant patients.
In fact, it has been argued that the theoretical potential of cART has already been reached [6].
Therefore, in the developed world with access to medication, HIV has become a chronic and
not a lethal disease.
2.2. The burden of lifelong cART
Implementation of cART has provided long-term suppression of viral replication, improving
the life expectancy and life quality of infected patients. Unfortunately, the economic burden
of cART is debilitating. According to the Centers for Disease Control and Prevention (CDC),
lifetime costs of treating HIV infection is estimated to be $379,668 per infected individual in
the United States [7].
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Moreover, patients on cART overtime can experience several side effects of cART such as:
cardiovascular diseases (e.g., myocardial infarction); non-AIDS cancers (e.g., anal cancer, liver
cancer, Hodgkin’s disease); liver, kidney, and bone disease as well as neurologic complications,
such as dementia [8]. Interestingly, most of these conditions are associated with the ageing
process. Hence, it is thought, that HIV infection controlled by cART accelerates ageing. And
importantly, HIV persists in a latent state that is not targeted by cART, rendering cART a
therapeutic management of the disease as opposed to a curative treatment. Thus, there is much
need to develop a curative therapy for HIV.
Figure 1. The viral replication cycle can be targeted pharmacologically at different stages
2.3. Clinical latency
The first step in finding a cure for HIV-1 infection is to identify the main source of cells that
carry silenced, replication-competent HIV-1. Therefore, it is critical to define which cells or
anatomical compartments constitute a reservoir of latent but replication-competent HIV-
infected cells.
HIV-1 infects cells expressing the cell surface CD4 receptor and either of the co-receptors CCR5
or CXCR4. These cells include T helper cells, monocytes, macrophages, and dendritic cells. In
vivo, HIV infects mostly activated CD4+ T-cells as quiescent and resting CD4+ T-cells are less
permissive to infection due to low expression of CD4 and CCR5, and minimal metabolism [9–
12]. The low metabolism is characterized by low levels of available dNTPs for reverse tran‐
scription and lack of energy sources [13–17]. Additionally, the cortical actin barrier in resting
cells is thought to inhibit virus entry, reverse transcription and nuclear import [18,19].
However, the biggest pool of latently infected cells comprises resting memory CD4+ T-cells.
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It is thought that these latent infections are predominantly generated while activated infected
cells revert back to a resting memory state [20–22]. During this process, as the genome of the
(partially) activated cell condenses and is silenced in transition to a memory state, so does the
HIV genome [14,15]. There is also evidence for direct infection of resting cells by HIV, resulting
in the generation of a latent infection [23]. Studying these cells in patients is challenging as the
frequency of latently infected cells in suppressed patients is very low, estimated to be 1 latent
cell per 1 million of uninfected cells [24,25]. Due to the long half-life of a latently infected resting
memory CD4+ T-cells (estimated at 44 months), cART would take over 70 years in order to
eradicate HIV from the infected patient [6,26,27].
Naive T-cells are also found to be latently infected; however, the frequency of such cells is even
smaller than resting memory cells [28]. Interestingly, the naive T-cell reservoir may increase
over time in suppressed individuals due to high proliferation of these cells compared to resting
memory cells [29].
HIV is found also in cells of monocyte/macrophage lineage such as macrophages in brain and
lung sections of infected individuals on anti-retroviral therapy [30,31]. However, proviral
transcription occurs in these cells at low levels; therefore, it is debatable whether these cells
are part of the latent reservoir [32,33].
Among the anatomical compartments affected by HIV-1, the central nervous system (CNS)
and gut-associated lymphoid tissues  (GALT)  are  two major  sites  [34–36].  The source  of
infection in the CNS is most likely infected monocytes, which are able to cross the blood–
brain barrier as the virus itself cannot [37–39]. Approximately 5-10 times more HIV-1 RNA
can  be  obtained  from  GALT  than  from  blood  cells  in  patients  receiving  cART  [40,41],
potentially  indicative  of  lower  penetrance  of  cART  in  cells  within  this  anatomical  site.
However, the contribution of these compartments to rebound of viremia after cART cessation
remains controversial [42,43].
2.4. Clinical proof-of-concepts for HIV-1 eradication
Thus far, only one patient, the so-called Berlin patient, was cured from HIV-1 after receiving
treatment for acute myeloid leukemia [44,45]. HIV eradication in this patient was accomplished
after several rounds of radio- and chemotherapy, total body irradiation, and two hematopoietic
stem cell (HSC) transplantations from a donor bearing homozygous thirty-two base pair
deletion in the CCR5 co-receptor gene (CCR5Δ32) were performed. The mutant CCR5 impedes
viral entry of R5 tropic viruses in the first phase of the infection [46–49]. It is estimated that
between 1% and 15% of the European Caucasian population harbor this mutation, while it
occurs less frequently in African and Asian populations [47, 48]. In this patient, cART was
ceased a day before the first transplant and after 7 years, no viremia or other indications of
viral replication have been detectable [52].
Following the success of the case of the “Berlin patient”, two HIV-1-positive patients, the
“Boston patients”, received HSCs transplants after developing Hodgkin’s lymphoma [53].
Both patients carried heterozygous CCR5Δ32 mutation. While still under cART regimen, no
viral production was observed which led to cessation of therapy. Unfortunately, after several
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months, strong viral rebound occurred in these patients. Follow-up analysis pointed to the
likely presence of a small refractory source of cells, which is thought to have seeded the viral
rebound; phylogenic studies revealed that only a few latent proviruses contributed to the viral
rebound [53]. Several other similar studies have been conducted with infected patients
suffering from either leukemias or lymphomas who received autologous or allogenic HSC
transplantation alongside cART as a strategy to deplete the latent pool of cells. However, in
most of these studies, viral rebound was detected following therapy interruption [54].
In another case, the Mississippi baby, an infant presumably infected in utero, received cART
30 h after birth. As newborns do not have resting memory CD4+ T-cells, it was reasoned that
cART will prevent establishment of the latent reservoir – the main impediment in eradication
strategies. One month after therapy, viremia reached undetectable levels and cART was
stopped after 18 months. Unfortunately, 2 years post therapy interruption, rebound of viremia
was detected (52, http://www.niaid.nih.gov/news/newsreleases/2014/pages/mississippibaby‐
hiv.aspx).
The immune system of rare “elite controllers” maintains low HIV-1 plasma levels, without the
need of medication for many years. Although the capability of these patient to control viral
replication is not completely understood, their circulating myeloid dendritic cells and CD8+
T-cells are more effective in depletion of infected CD4 T-cells [56–61]. Interestingly, the ARNS
VISCONTI cohort showed that cessation of long-term cART, started during the acute phase of
HIV-1 infection, resulted in post-treatment control (PST) of infection. Fourteen of the studied
individuals were able to keep or even further reduce the viral reservoir. Furthermore, these
individuals were able to maintain long-lasting, low level of viremia [62]. Recently, a perinatally
infected baby displayed more than 11 years of HIV-1 remission. At 3 months of age, plasma
HIV-RNA reached 2.1 x 106 copies/ml, and cART was administered for about 5–6 years. At 6.8
years of age, no HIV-1 RNA was detectable and cART was discontinued. After more than 12
years, plasma viremia still remains undetectable [63]. Therefore, this case provides the first
evidence that early initiated, long-term cART can result in stable and durable HIV-1 remission.
Data from the Berlin and Boston patients provided a rationale for the creation of HIV-resistant
cells. Since the CCR5Δ32 homozygous mutation is not lethal and not associated with abnormal
immune functions [52], many approaches to silence the CCR5 gene have been or are under
investigation [64–67]. These studies all employ genome editing technologies such as tran‐
scription activator-like effector nuclease (TALEN), clustered regularly interspaced short
palindromic repeats (CRISPRs) or zinc-finger nucleases (ZNFs), which target the genome with
high specificity and introduce deletions in the sequence of interest, in this case in the DNA
sequence of CCR5 or/and CXCR4 co-receptors [64,65,68]. The rationale for this approach is
based on the notion that cells bearing mutated CCR5 protein are not permissive to infection
with R5 HIV-1 viruses, while cells with a mutated CXCR4 are resistant to C4 viruses. The
double knock-out of both CCR5 and CXCR4 would allow resistance to infection regardless of
viral tropism. However, the safety of such an approach remains to be elucidated. Uninfected
HSCs isolated from infected individuals are engineered with either technology and then
transfused back into patients. The ZNF approach targeting CCR5 has shown some promising
results, although the sizes of cohorts used have been small. Gene-modified cells persisted in
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patients over 9 months, and cells seemed to expand and undergo trafficking to other tissues
[66]. An increase in CD4+ T-cell counts was observed in all individuals. Importantly HIV-1
DNA in the blood decreased. The encouraging outcome of this study has resulted in phase II
clinical trials.
Another gene therapy-based approach is the introduction of HIV-1 expression-dependent
suicide genes encoding either toxic or pro-apoptotic proteins such as members of the Bcl-2
protein family. Constructs that are responsive to Tat and Rev viral proteins were tested [69].
While obtaining encouraging results, activity of such suicide genes only affects cells that are
actively producing viruses, thus the latent pool of cells would still be unaffected.
Despite many attempts at HIV-1 cure, thus far only two cases, the "Berlin patient” and the early
treated infant have resulted in eradication [44,45,63]. Due to safety and economic issues
associated with transplantation and gene therapy approaches, broad use of such a therapeutic
approach is not feasible for HIV cure. Moreover, the gene therapy approach provides a
functional rather than sterilizing cure. Nevertheless, all these studies provided valuable
insights into the biology of the latent reservoirs. They constitute a proof-of-concept for HIV-1
cure. Moreover, it seems that immediate initiation of cART contributes to restricting the
establishment of the latent pool.
These studies highlight the need for more robust, cheaper, and feasible treatments in order to
achieve HIV-1 eradication among all infected individuals. In 2004, the concept of so-called
“shock and kill” or “kick and kill” therapy was proposed [70–72]. The aim is to specifically
reactivate proviruses in latently infected cells (“shock”) and eliminate the infected cells via
viral cytophatic effects or/and render the cells susceptible to immune clearance (“kill”). New
rounds of infection would be prevented by cART. “Shock and kill” therapy relies on the
identification of potent and specific latency reversal agents (LRAs) alongside induction of an
effective immune response against the reactivated latent pool of cells. The LRAs currently
under investigation do not result in sufficient reactivation of latent HIV in vivo. Therefore,
novel molecules that specifically reactivate latent HIV-1 are urgently needed.
3. Model systems and assays to detect and study HIV-1
To study the complex nature of HIV-1 latency, reliable model systems are required that
recapitulate the nature and dynamics of the latent reservoir in vivo. Several cell lines of
lymphocytic or monocytic lineage, primary-cell models, as well as animal models, are used to
study HIV latency [73].
3.1. Cell lines
Immortalized cell lines of T-cell and monocytic origin are cost-effective and easy to use in the
study of latent HIV. They allow fast read-outs in large scale for mechanistic molecular
characterization of HIV gene expression. Therefore, cell lines are an attractive platform for
screening and mechanistic characterization of LRAs. To generate a latent cell line, cells must
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first be latently infected with a HIV derived virus. Several different HIV derived viruses are
used ranging from full length to minimal virus and can make use of a wide range of reporter
constructs (e.g. GFP or luciferase). The viral Tat/TAR axis is of vital importance for the
transcriptional regulation of HIV and can be included or excluded from the viral construct
used. Latent infection of relevant cell lines derived from T-cells or monocytic lineage, depend‐
ing on reservoir of interest generate cell lines that can be used to study the molecular mecha‐
nisms of HIV latency [74–78].
Ach-2 and U1 cells are characterized by low expression of HIV-1, which can be strongly
upregulated upon TNFα or mitogens stimulation [74,79]. However, in these cell lines, latency
results from mutations in Tat protein (U1 cell-line) or in RNA stem loop TAR (Ach-2) [76,77].
Therefore, these cell lines do not represent complexity of latency found in vivo, however, they
do allow Tat/TAR-independent HIV-1 reactivation investigation.
A more appropriate system to study latency are J-Lat cell lines derived from Jurkat cells of T-
lymphocytic origin [78, 80,81]. These cells have integrated replication-competent full-length
or minimal proviral constructs with an intact promoter and Tat-TAR axis, a GFP reporter gene
replaces the Nef sequence in full-length proviruses or is located downstream of Tat in minimal
proviruses [78].
These cell lines have been extremely useful to delineate the molecular requirements of HIV
transcription activation and silencing. Although useful for molecular analysis and screening
platforms, the cell line model systems of HIV latency also present some limitations; first, clonal
cell lines are derived from a single integration event, and therefore do not reflect the diverse
distribution of integration sites in the host chromatin [82,83]. Consistently, results vary
depending on the cell lines used, indicating possible clonal cell line effects [84]. Due to the
above mentioned limitations and the considerable difference between cell line models and
primary cells in terms of proliferative capacity, genomic stability and mechanisms involved
in establishing and maintaining latency, generally latency models based on primary cells are
preferable.
3.2. Primary cells
To more closely resemble infection in vivo and validate putative LRAs more accurately, several
primary cell models have been developed. Depending on the cell status at infection, these
models can be divided into two groups.
The first group relies on purification of CD4+ T-cells from healthy donors, that are then
activated and subsequently infected. Depending on the method, CD4+T-cells are purified and
stimulated with a-CD3/IL-2 [85], a-CD3/aCD-28 [86], a-CD3/aCD-28/IL-2 [87], or Ag-MDDC
(antigen-loaded monocyte-derived dendritic cells; [88]), and infected with virus. Productively
infected cells die due to virus-induced apoptosis or become latent by reverting back to a resting
state. To limit infection to only one replication cycle, replication-defective viruses or antire‐
troviral drugs are also used. The rationale for these systems rely on the notion that a portion
of activated, infected CD4+ T-cells transition to a quiescent state, shutting down general
transcription and slowing down metabolism, resulting in latency [6,25,28,89–91]. Depending
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on the method used, different populations of latently infected cells are generated for use in
reactivation studies. In the methods suggested by Sahu and Marini central memory T (TCM)
cells remain in culture, in Yang’s protocol mainly effector memory T (TEM) cells are produced,
in Bosque and Planelles’s method cells phenotype resembles central memory-like (TCM). The
main disadvantage of these methods is the time needed to obtain results, which varies from 1
to 4 months. Furthermore, they are labor-intensive and technically challenging.
The second group uses direct infection of resting memory CD4+ T-cells, which immediately
after integration become latent. Cells are infected after purification and can be used after
several days for reactivation studies [90, 91]. Stimulation of CCR7, CXCR3, or CCR6 receptors
increases the susceptibility of resting memory CD4+ T-cells to infection without T-cell activa‐
tion. In the methods of Swiggard and Lassen, central memory T (TCM) and effector memory T
(TEM) cells are the source of latent HIV-1; in Saleh’s method naïve resting memory T-cells, in
addition to TCM and TEM cells, constitute the latent pool. The main advantage of these methods
is the time needed to evaluate the potency of putative LRA, as results can be obtained within
one week.
Depending on the protocol used, the amounts of cells that become latent differ from as little
as 1% to up to 40%. In models where cells are activated, on average more latently infected cells
are generated. Using these models, we can quantify the level of reactivation of HIV-1 in a
reliable manner by measuring the production of the viral protein p24 by enzyme-linked
immunosorbent assay (ELISA) or quantification of viral transcription by quantitative RT-PCR,
or by detection of GFP/luciferase in case of reporter-based constructs.
A novel detection method distinguishes uninfected, productively infected, and latently
infected cells using a dual reporter system. A modified HIV-1 derived genome containing GFP
as a reporter of viral transcriptional activity and mCherry under an EF1a promoter as a reporter
of infection (latent or productive) allows easy isolation of the different cell populations [23].
Ultimately, the golden standard for testing activity of LRAs are primary cells from infected
individuals under cART obtained by leukophoresis, a process in which white blood cells are
specifically isolated while other blood components are reverted back to the patients’ circula‐
tory system. The isolated cells are uninfected, latently infected, and infected with defective
viruses. Large amounts of CD4+ T-cells are required and isolated from patients for testing
LRAs.
The development of primary cell models greatly improved the quest for LRAs, yet results differ
between each model system [84]. No in vitro models completely recapitulate the full range of
latent cells in vivo; instead, only a small sub-fraction of latently infected cells is represented.
Hence, the validation process of putative LRAs requires testing on cells derived from infected
individuals [93].
3.3. Animal models of HIV-1 infection
The number of animal models available to study latency is limited. The toxicity of putative
LRAs can be assessed with use of mouse and non-human primate (NHP) models [94]. Two
mouse models have been developed and used in HIV latency studies: the humanized SCID
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(SCID-hu) mouse, transplanted with human thymus and liver fragments, and the humanized
blood, liver, and thymus (BLT) mouse which has a human immune system with full mucosal
immunity [95–97]. Unfortunately, SCID-hu mice do not express human proteins involved in
the viral replication cycle; therefore, the study of HIV-1 in these mice is restricted to events
taking place within organs of human origin in this model. In addition, HIV-1 is not responsive
to cART in these animals. BLT mice are a better model of HIV-1 infection, as they produce
resting memory CD4+ T-cells of human origin. However, some components of cART do not
repress replication in BLT mice [34].
NHP models employ the Simian immunodeficiency virus (SIV) infection in rhesus and pig
tailed macaques to recapitulate HIV-1 infection in humans [98,99]. NHP models allow the
monitoring of the spread of infection. Moreover, infection in this model can be controlled by
antiretroviral therapy. NHP models are helpful in studying the first stages of latency estab‐
lishment, as investigating this part of HIV-1 infection is extremely challenging in patients, as
the pool of latently infected cells is established early during infection [100]. One caveat to the
use of SIV-based NHP models of HIV latency is that the viral 5′LTR or promoter of SIV is
considerably different in sequence from HIV-1 [101] and therefore latent SIV response to LRAs,
which is a direct consequence of promoter-mediated transcription activation may vary
substantially from latent HIV-1. In addition, animal models are far more expensive than cell-
based systems. Nor do they fully reflect human infection or metabolism. Finally, ethical
concerns are inherent to the use of NHP models of HIV latency.
3.4. Detection of the latent reservoir
The study of latent HIV infection requires accurate measurement of the size of the latent
reservoir and the extent of reactivation following LRA treatment. Depending on the experi‐
mental aim, different detection methods can be employed. These methods generally rely on
PCR, protein quantification, or reporter detection.
The quantitative viral outgrowth assay (QVOA) is a well-established method to estimate the
latent pool. The assay relies on the use of serial dilutions of cells obtained from an infected
individual in co-culture with uninfected cells that are permissive to infection. Viral proteins
are detected by ELISA. Unfortunately, QVOA is time-consuming, costly, and might generate
false-negative results as not all replication-competent proviruses are reactivated, and thus not
detected [83].
The HIV reservoir can be approximated by detecting the number of viral DNA copies present
in the cells. The recently introduced digital droplet PCR (ddPCR) improves on classic and
nested qRT-PCR by simultaneously amplifying thousands of nanoliter reactions in combina‐
tion with very sensitive detection system based on flow cytometry [94,102,103]. ddPCR is
therefore superior to nested qRT-PCR in its ability to resolve rare events such as latent HIV-1.
Although PCR based methods provide increased sensitivity for the detection of viral genetic
material, these approaches also detect defective proviruses, which results in false-positive
results.
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Another recent PCR-based method for reservoir detection evades false positive results from
defective proviruses. The Tat/rev induced limiting diluting assay (TILDA) relies on PCR
amplification of multiply spliced RNA (msRNA) of tat/rev transcripts that are present in
productively infected cells and absent in latent infection [104]. Small amounts of cells isolated
from patients are divided into two equal parts and distributed in limiting dilution. One half
is left unstimulated while the other is activated with PMA/Ionomycin. After 12 hours, cells are
lysed and subjected to ultrasensitive nested RT-PCR. By employing statistical modeling, the
frequency of cells that are expressing msRNA in both groups is estimated and based on the
unstimulated group a threshold of activation can be set. Using the TILDA assay, the size of
the reservoir is estimated at 24 cells per million, which is more than measured by QVOA but
less than measured by PCR methods [24,83,104]. The assay more accurately estimates the true
size of the latent reservoir, is highly sensitive, reproducible, fast, relatively inexpensive, and
requires only 10 mL of patients’ blood. However, a limitation on the TILDA assay is that it
detects the presence of viral transcripts but not the production or release of infectious viral
particles; therefore, it may still overestimate the true size of the reservoir, yet to a smaller extent
than other PCR-based methods. Additionally, signal detection relies on amplification of highly
variable region of the HIV-1 DNA; therefore, detection of all subspecies of HIV-1 might be
challenging and require extra optimization steps.
Unfortunately, all current methods to detect latent HIV-1 have limitations. First, the pool of
latently infected cells in patients is extremely low, resulting in a high noise-to-signal ratio.
Furthermore, defective or hyper-mutated proviruses are detectable by PCR-based techniques,
yet irrelevant for eradication strategies. Moreover, not all replication-competent proviruses
are inducible in the first round of treatment, yet get reactivated upon subsequent rounds of
stimulation [83]. Thus, assays to measure latency reversal are overestimating – in the case of
PCR-based methods – or underestimating – in the case of QVOA – the latent pool. This poses
a main problem in measuring efficiency of the reactivation of HIV-1. A captivating approach
employing the use of a biomarker (e.g., gene), which responds to treatment in the same way
as HIV-1, would allow more easily quantifiable assessments as to whether latent HIV in patient
cells would be responsive to a particular treatment.
4. Molecular mechanisms of latency
Although replication-competent, latent HIV is transcriptionally silenced but susceptible to
reactivation upon certain stimuli. Following integration into the host genome, transcription
from the HIV genome is controlled by key cellular host factors, and subject to host cell gene
regulation similar to endogenous genes. Since viral transcription initiation, elongation, and
termination are tightly regulated by host proteins, HIV is also widely used as a model system
to study gene regulation.
4.1. Host antiretroviral mechanisms thwart infection
Host defense mechanisms impede HIV-1 infection. Upon entering the cell, HIV’s RNA genome
is reverse transcribed into double-stranded DNA (dsDNA). This process requires freely
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available deoxynucleotide triphosphates (dNTPs). By limiting the pool of freely available
dNTPs, the nucleotide scavenger SAMHD1 restricts viral replication in non-cycling myeloid
cells and quiescent CD4+ T-cells [105–108]. Additionally, SAMHD1 has 3′–5′ exoribonucleases
(RNAse) activity that specifically cleaves single-stranded RNA [109,110]. Interestingly, Vpx,
encoded by HIV-2 and Simian immunodeficiency virus, is an accessory protein packaged into
the virion, which induces SAMHD1 degradation [111].
Additionally, APOBEC3G limits viral replication by catalyzing the deamination of cytidine to
uridine in the viral single-stranded DNA (ssDNA) genome during reverse transcription [112].
Interestingly, APOBEC3G is inactive in memory CD4+T-cells, which helps to explain why this
cell type is more permissive to HIV-1 infection. Therefore, activated CD4+ T-cells are the main
target cell type of HIV infection and of the main source of the latent reservoir.
4.2. Integration of HIV into the host genome required by host factors
The reverse-transcribed viral DNA genome is incorporated in the pre-integration complex
(PIC). The PIC is imported into the nucleus. Host factors identified so far that affect viral
integration are lens epithelium-derived growth factor (LEDGF/p75/PSIP1) and hepatoma-
derived growth factor related protein 2 (HRP- 2/ HDGFRP2), through an integrase binding
domain. In the absence of LEDGF, provirus integration is decreased 10-fold and HIV’s pattern
of integration is altered [113–115]. Simultaneous LEDGF and HRP-2 knockdown further
decreases viral replication [116]. Nevertheless, knockdown of both factors does not completely
abolish HIV-1 integration, indicating that IN alone and/or in cooperation with other host
factors can still integrate the viral genome [117]. PIC nuclear import stimulates export to the
cytoplasm of INI-1 and PML, disrupting this effect greatly improves integration efficiency
[118–120]. Upon knockdown of transportin-3/TNPO3 and nuclear pore protein RanBP2/Nup35
HIV-1 integrates randomly [121]. Therefore, nuclear import affects the site of integration with
a preference for open chromatin.
4.3. Pre-integration vs post-integration latency
Two states of latency can be defined based on the integration state of HIV: pre-integration
latency and post-integration latency. Defects in integration or in a prior phase of the viral
replication cycle (e.g., incomplete reverse transcription) might result in unintegrated viral
DNA. The half-life of the linear pre-integration complex is approximately 1 day [122]. The
linear unintegrated viral DNA can also be circularized, resulting in slightly extended half-life
of the virus [123]. In quiescent cells, the pre-integrated virus can reside near the centromere
for weeks [124]. Unintegrated virus can replicate, albeit very inefficiently [125]. The half-life
of both forms of unintegrated virus is too short and replication inefficient to serve as the source
required for the long-term persistence of latent HIV making pre-integration latency less
clinically relevant.
Post-integration latency occurs when the HIV virus is stably integrated into the host genome,
but a productive infection is not achieved. The site of integration and the abundance of
transcription factors are crucial for determining whether an infection will be latent or produc‐
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tive. The site of integration will determine the chromatin environment (such as histone
modifications), relative position to other genes (intronic insertion vs gene desert) and position
within the nucleus of the provirus.
4.4. Integration biases
The site of integration greatly determines the transcriptional activity of the provirus. HIV
preferentially integrates into active genes both in patient material and transformed cell lines
[82,126–128]. Moreover, HIV-1 integrates in regions of genome that are in close proximity to
nuclear envelope [129]. Latent integrations are in or close to alphoid repeat elements in
heterochromatin, whereas productive integrations avoid insertion in or near heterochromatin
[78]. Integration is associated with transcription-inducing histone modifications (i.e., H3 & H4
acetylation and H3K4 methylation) but not transcription-inhibiting modifications (i.e., H3K27
trimethylation and DNA CpG methylation) [130]. A comparison of integration sites in resting
and activated CD4+ T-cells showed that in both cell types HIV integrates in active genes.
However, in activated cells, insertions were enriched for gene dense, CpG island-rich and high
G/C-content regions [131]. Latency in infected Jurkat cell lines correlated with integrations in
gene deserts, centromeric heterochromatin, and highly expressed cellular genes [128]. Within
the nucleus, HIV-1 is located mostly in decondensed chromatin at the nuclear periphery, while
it disfavors heterochromatic regions [132]. Interestingly, latent proviruses were found to
interact with a pericentromeric region of chromosome 12 in quiescent cells [133]. In a study of
viremic progressors and viremic controllers, integration was enriched into, or in close prox‐
imity to, Alu repeats, local hotspots, and silent regions of the genome [134]. In addition, close
proximity of the provirus to PML bodies is associated with latency, an association that is lost
upon reactivation [135].
4.5. Integration relative to host genes affects transcriptional state of the provirus
Sense and antisense integration relative to host genes can greatly affect the transcriptional state
of HIV. Integration in sense orientation can lead to promoter occlusion, whereas integration
in antisense orientation can lead to collision of the transcriptional machinery. Promoter
occlusion occurs when the transcriptional machinery is depleted from the viral promoter by a
dominant host promoter that is transcribed and negatively affects proviral expression.
Indeed, chimeric transcripts of the host gene and in sense viral integrations were observed
[136,137]. Additionally, Han et al. compared the effect of sense and antisense insertions of HIV
relative to the active HPRT gene [138]. In this setting, sense integration enhanced viral
expression whereas antisense integration (transcriptional collision) led to suppression. Sense
integrations were shown to be modestly preferred in latent cells, a preference that was not
present in productively infected cells [139]. Transcriptional interference and transcriptional
collision are examples of host genes interference with viral expression. On the other hand,
reactivation of HIV may lead to suppression of host gene expression [136]. Indeed, in a cell
model with a latent integration into the HMBOX1 gene, the host gene was repressed upon viral
reactivation [140].
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4.6. Viral transcription starts at the 5'LTR
The provirus is flanked by a 5′ and 3′ long terminal repeats (LTRs). While transcription can be
initiated from both LTRs, the 5′ LTR is dominant and serves as the HIV promoter, although 3′
transcription is activated when the 5′ LTR is defective [141]. Transcriptional interference has
been proposed as the mechanism by which the 5′ LTR exerts its dominance over the 3′ [142].
Interestingly, low-level antisense transcription takes place at the 3′ LTR, a mechanism by which
latency can be maintained [143–147]. Sense transcription results in at least 40 coding transcripts
due to alternative splicing of the HIV-1 genome [148]. Finally, both LTRs also act as a source
of negative sense transcription, which could potentially affect the expression of neighboring
genes [149,150].
4.7. The 5′ LTR contains numerous putative transcription factor binding sites
HIV-1 encodes a potent trans-activating protein – Tat – that drives viral expression during
productive infection. However, initially, before sufficient levels of Tat are expressed, the
provirus relies on host factors to initiate transcription. The 5′ LTR contains three regions – U3,
R, and U5 (Figure 2) [151]. The R region, immediately next to the transcription start site (TSS),
contains the trans-activation response (TAR) element, an important regulator of HIV expres‐
sion. The U3 region contains the core promoter (nucleotides –78 to –1 upstream of TSS), a core
enhancer (nucleotides –105 to –79), and a modulator region (nucleotides –454 to –104)
[152,153]. The core promoter contains three Sp1 binding sites in tandem, a TATA box, and an
initiator element at the transcription start site. The core enhancer contains two NF-kB-binding
sites. The modulator region – so-called because early experiments with deletion upstream of
the LTR caused increased activity of the LTR – was shown by later experiments to contain
binding sites for both repressive and activating factors including nuclear factor of activated T-
cells NFAT, STAT5, NF-kB p65/p50 heterodimers, lymphocyte enhancer factor (LEF-1),
CCAAT/enhancer binding protein (C/EBP) factors, AP-1, and activating transcription factor/
cyclic AMP response element binding (ATF/CREB) factors (Figure 2) [152,154–162]. It is well
established that these transcription factors have binding sites within HIV-1 sequence. More‐
over, they are strong activators of HIV-1 transcription of which NF-κB is considered the most
critical [163–166]. In addition to the presence of these sites, bioinformatic tools indicate that
this region of the HIV LTR contains a tightly clustered distribution of multiple transcription
factor consensus binding elements [167].
4.8. Positive host factors bind to the 5′ LTR
Initial transcription of HIV-1 is entirely dependent on host factors. Nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-kB) is a hetero dimer comprised of p50 and p65
subunits involved in T-cell activation. NF-kB acts as a transcription factor and is a potent
activator of HIV-1 transcription initiation and elongation. It interacts and functions coopera‐
tively with numerous proteins. Independent of Tat, NF-kB can reactivate HIV to high expres‐
sion levels [168]. Mutated NF-kB-binding sites on the LTR inhibit basal transcription and Tat
transactivation [169]. NF-kB, Sp1, and other factors (LEF-1, Ets1, and TFE-3) bind to sites near
NF-kB sites and synergistically activate HIV transcription, even in the presence of repressive
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chromatin structures [170,171]. NF-kB and AP-1, a heterodimer of proteins from the c-Fos, c-
Jun, ATF, and JDP families, cooperatively trans-activated LTR activity through the ERK1/ERK2
mitogen-activated protein kinase (MAPK) pathway [161]. Acetylation of Lys310 in NF-kB p65
subunit is an activating mark that is removed by NAD+-dependent protein deacetylases SIRT1
and SIRT2 [172]. Tat positively affects NF-kB by inhibiting SIRT1 and stimulating degradation
of IkB, a protein that sequesters NF-kB in the cytoplasm [169,173]. The viral nucleocapsid (NC)
protein enhances NF-kB-mediated activity by interacting with the LTR [174]. p65 recruits
THIIH which is part of the preinitiation complex and its subunit CDK7 with kinase activity
activates CDK9, resulting in increased HIV transcription [175,176]. The cell surface receptor
OX40, bound by its ligand gp34, activates transcription from 5′ LTR, in a manner dependent
on the presence of NF-kB-binding sites on the LTR [177]. The transcription factor E2F-1, a
regulator of S-phase gene expression, inhibits LTR transcription through the recruitment of
p50 at the NF-kB-binding sites on the LTR [178].
Members of the SV40-promoter (Sp) specific transcription factor family regulate LTR activity.
Sp1 and Sp4 are activators of HIV-1 [179]. Expression of Sp transcription factors changes during
monocytic maturation, suggesting differences in susceptibility to LTR activation during
differentiation [180].
Nuclear factor of activated T-cells (NFAT) can induce LTR activity in T-cells [155]. NFAT
recruits HATs through CBP/p300, which results in reactivation of HIV-1 transcription [181].
The Janus kinase (JAK)/signal transducers and activators of transcription (STAT5) can
stimulate or inhibit HIV transcription. STAT5 binds to its binding sites in the U3 enhancer
region on the LTR where it promotes transcription [156]. In response to a broad range of
cytokines (e.g., IL-2, IL-7, IL-15) and granulocyte-macrophage colony-stimulating factor (GM-
Figure 2. The genome of HIV-1
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CSF) JAK-mediated phosphorylation of a C-terminal tyrosine residue activates STAT5A and
STAT5B. Homodimers or heterodimers of activated STAT5A and STAT5B translocate to the
nucleus to stimulate HIV expression [182,183]. Interestingly, STAT5Δ, an isoform of STAT5
truncated on the C-terminus, acts as a repressor of LTR activity [184]. Indeed, in the promon‐
ocytic cell line U1 high levels of STAT5Δ are present. Upon stimulation with GM-CSF,
STAT5Δ blocks RNAPII from binding to LTR U3 region, inhibiting activity of HIV promoter
[185]. STAT5Δ promotes p50 homodimers binding to the LTR, contributing to latency main‐
tenance [186].
In monocytes and macrophages, CCAAT/enhancer binding protein (C/EBP) factors are crucial
for activation of HIV-1 [160,187–189]. C/EBP, a member of the bZIP superfamily, contains a
DNA-binding domain and a leucine zipper for homo- and heterodimerizations. Similar to Sp-1,
levels of C/EBP vary during myeloid development [190]. Interestingly, the HIV-1 LTR contains
several C/EBP binding sites [159].
Some studies employing mutagenesis of binding sites for activator protein-1 (AP-1) within
proviral genome showed that AP-1 transcription factor is the crucial activator of proviral
transcription, as proviruses with altered AP-1-binding sites were less prone to reactivation
even if treated with strong activator such as phorbol 12-myristate 13-acetate – PMA [191].
Furthermore, the latent pool was bigger in cells infected with a virus carrying a deletion in
AP-1 sites, implicating that the AP-1 protein is necessary for successful provirus transcription
[192]. Heterodimeric protein AP-1 is formed upon phosphorylation od c-Jun N-terminal kinase
(JNK) in JNK/MAPK pathway [193]. It is well established that activation of TLR signaling
induces nuclear localization of NF-kB and AP-1 mediated via JNK pathway [194–196].
In addition to the already mentioned host factors, the potent viral trans-activating protein
Tat and to a lesser extent the multifunctional viral protein, viral protein R (Vpr), positive‐
ly affect viral transcription. Productive infection requires the presence of Tat. Exogenous
expression of Tat rescues HIV from latency [197]. A defective Tat mutant (C22G) is incapable
of full-length viral expression [198]. Additionally, the Tat mutant (H13L) is more prone to
establish latency [197]. Tat recruits the positive transcription elongation factor b (P-TEFb),
which shifts RNAPII promoter proximal pausing to transcriptional elongation leading to a
productive  infection  [199,200].  P-TEFb  consists  of  CDK9,  a  serine/threonine  kinase,  and
CyclinT1. The N-terminal cystein-rich region of Tat (Cy22-Cy37) binds to CycT1 through
Zn2+-mediated interactions [201–203].
Vpr is a multifunctional HIV-1 protein that plays a role in nuclear import of the PIC and cell
cycle arrest in proliferating cells. Vpr also activates LTR activity through multiple mechanisms.
Vpr recruits p300 to the 5′ LTR increasing acetylation, resulting in HIV-1 transcription [204].
Moreover, Vpr interacts with Sp1 and TFIIB, part of the transcription initiation complex,
stimulating proviral transcription [204–206].
4.9. Repressive host factors at the 5′ LTR
Not all host transcription factors have an activating effect on LTR activity (Figure 3). YY1 and
LSF recognize binding sequences in the LTR and repress transcription through epigenetic
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modification [207]. C-promoter binding factor-1 (CBF-1) also represses HIV through epigenetic
silencing [208,209]. c-Myc recruits an epigenetic silencing factor to repress HIV-1 [210].
Transcription factors initiate LTR activity, but full-length transcripts are not produced because
transcription elongation is inhibited. DRB sensitivity-inducing factor (DSIF), a heterodimer
composed of hSpt4 and hSpt5 proteins, induces capping of RNA from newly initiated
transcription complexes [211]. The subunit hSpt5 interacts directly with nascent RNA as it
appears from the RNAPII exit site and recruits negative elongation factor (NELF) (Figure 3)
[212–214]. Escape of transcripts from the promoter proximal pause site is prevented by NELF,
which induces termination of transcription over several hundred bases [215]. Moreover, the
binding sequence of NELF subunit E recognizes a homologous sequence on TAR, increasing
association of NELF with the LTR, which results in transcription silencing. Indeed, experi‐
ments where NELF is knocked down show higher basal HIV transcription and reactivation
from latency [216–218].
A novel, RNA interference independent, mechanism mediated by microprocessor and
termination factors causes transcriptional silencing and chromatin remodeling at the HIV-1
promoter [219]. Microprocessor binds to TAR, which is then cleaved by Drosha into two RNAs,
a 5′-end and 3′-end product. The 5′ is further processed in an Rrp6-dependent manner into a
transcription repressing RNA species. The 3′ RNA recruits termination factor Xrn2 and Setx,
which induces RNAPII pausing and premature termination of transcription [219].
Figure 3. Molecular mechanisms in latent and productive HIV-1 infection
4.10. Host factors induce transcriptional initiation, but not elongation
While some host transcription factors recruit RNAPII, in the absence of Tat, transcription
elongation does not occur resulting in the generation of short abortive transcripts by promoter
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proximal pausing [220,221]. These ~60nt transcripts include TAR, which has a stem-loop
structure and binds near the HIV 5′LTR, inhibiting RNA-polymerase. TAR directly binds Tat,
which recruits transcriptional elongation complex to the LTR [222].
4.11. Tat-dependent transcription leads to productive infection
If cells become activated or due to leaky transcription, Tat can be produced. Tat binding to P-
TEFb induces significant conformational changes in P-TEFb, allowing Tat and CycT1 to
cooperatively recognize and stably bind TAR [200,223].
Tat-P-TEFb phosphorylates NELF-E resulting in the dissociation of NELF from TAR and the
paused RNAPII complex [214,216,218,224]. CDK9 phosphorylates RNAPII at the carboxyl
terminal domain (CTD) at Ser2 and Ser5 residues of the 52 heptad repeats, which regulates
progression to the elongation phase of transcription [225–227]. The phosphorylation status
determines regular and alternative RNA splicing and the 3′ end recruitment of polyadenyla‐
tion factors [228,229]. Ser2 phosphorylation of the RNAPII CTD recruits splicing-associated c-
Ski-interacting protein, SKIP, and stimulates elongation transcription and alternative splicing
of the Tat-specific splice site through interactions with U5snRNP proteins and tri-snRNP110K
[230].
Phosphorylation of hSpt5, a subunit of DSIF, by CDK9 converts it into a positive elongation
factor that prevents nascent RNA from breaking of from the transcription complex prema‐
turely and inhibits pausing of RNAPII at arrest sites [231,232]. By removing several blocks Tat-
P-TEFb induces transcriptional elongation as well as co-transcriptional processing. During
active transcription elongation, increased recruitment of RNAPII to TSS maintains a stable
level of RNAPII at the promoter proximal region [218]. Throughout transcription, Tat-P-TEFb
remains associated with the elongating transcription machinery [231,233,234].
4.12. P-TEFb can be recruited in active and inactive form in the nucleus by Tat
In activated T-cells, inactive P-TEFb predominantly resides in the 7SK small nuclear ribonu‐
cleoprotein (snRNP) complex (Figure 3) [235–237]. The 7SK snRNP complex consists of 7SK
snRNA, HEXIM1 (or its homolog HEXIM2), the La-related protein 7 (LARP7), and the 7SK-
specific 5′ methylphosphate capping enzyme (MePCE). The snRNA functions as a scaffold: it
binds two units of P-TEFb and one HEXIM1/2 homo-/heterodimers [238,239]. MePCE and
LARP7 protect the 7SK RNA from nuclease degradation, MePCE binds the 5′ end, LARP7 the
polyuridine 3′ end [240–242]. Tat disrupts the interaction between pTEFb and HEXIM1/7SK
snRNA and recruits P-TEFb to 5′ LTR, resulting in active transcription [226].
BRD4 can also recruit P-TEFb from 7SK snRNP [241,243], to promote transcription. Due to
similarities in their C-terminal P-TEFb interacting domains [244], Tat and BRD4 compete for
P-TEFb [245,246]. In a latent model, knockdown of BRD4 results in Tat-dependent reactivation
of HIV-1 [247].
Bromodomain and extra-terminal domain family of proteins (BET) play an important role in
repression of the HIV-1 transcription. BET proteins are responsible for the recruitment of P-
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TEFb to transcribed genes [246,248]. BRD4 competes with viral protein Tat for binding site on
pTEFb, and it represses HIV-1 transcription [245,246]. Knockdown of BRD2 indicates this
protein contributes to the maintenance of latency. These results are consistent with the notion
that BRD2 is binding to remodeling factors such as HDACs [249,250].
P-TEFb can be recruited to transcription complexes by other factors. CTIP2 recruits P-TEFb by
binding HEXIM1 and negatively regulates the complex by repressing the CDK9 kinase activity
of P-TEFb [251]. Phosphorylation of HEXIM1 at Tyr271 and Tyr 274 decreases retention of P-
TEFb in the 7SK RNP [252]. Additionally, through the binding of nascent RNA, SRSF2 and P-
TEFb are released from the 7SK complex and induce transcription elongation in a manner
similar to TAR/Tat-mediated recruitment of P-TEFb [253].
4.13. P-TEFb is a subunit of the super elongation complex
P-TEFb is required for activation of HIV transcription but does not explain the maximum
observed viral expression; therefore, additional factors are necessary [254,255]. P-TEFb is an
integral part of the super elongation complex (SEC) (Figure 3), which is a potent activator of
transcriptional elongation of host genes [234,256]. It is composed of one of two scaffold
proteins, AF4/FMR2 proteins AFF1 or AFF4. Translocations of AFF1 and AFF4 resulting in
fusion proteins are commonly found in mixed lineage leukemia (MLL) [257–259]. The resultant
fusion proteins cause aberrant recruitment of SEC to MML-specific genes [260]. AFF1 and AFF4
recruit many other proteins to the SEC [261], such as ELL family of elongation stimulatory
factors ELL1 and ELL2, which inhibit RNAPII pausing and synergistically improve Tat-
transactivation with P-TEFb [256]. Moreover, knockdown of ELL2 strongly suppresses viral
expression. [203,210,230,252]. Tat and AFF4 inhibit the polyubiquitination-mediated degra‐
dation of ELL2, increasing available levels of SEC. [256,262].
4.14. Tat can be extensively post-translationally modified – “Tat code”
Modifications on numerous amino residues of Tat regulate the interaction with a wide variety
of host proteins. In comparison to the histone code which is used to explain the multiple
modification on histone tails and their function, a “Tat-code” has been proposed [34]. Tat is
phosphorylated on Ser16 and Ser 46 by CDK2, modifications which result in transcription
inhibition [263]. Acetylation of Lys28 increases affinity for P-TEFb binding and is removed by
HDAC6 [264–266]. Tat dissociates from TAR and binds acetyltransferase PCAF which
acetylates Tat at Lys50 and Lys51 [264,265,267–270]. Acetylated Lys50 allows recruitment of
the PBAF (SWI/SNF B) chromatin remodeling complex to the LTR [267,271–273]. SIRT1
deacetylates Tat at Lys50 as part of a late phase of transcriptional regulation, striping Tat of
acetyl groups allowing its reuse in subsequent rounds of transcriptional cycles [274]. Mono‐
methyl-transferase Set7/9 and LSD1, respectively, methylate and demethylate Lys51. Deme‐
thylated Lys51 of Tat enhances HIV-1 transcription [275,276]. Hdm2 polyubiquitinates Lys71,
activating Tat [277].
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4.15. Nucleosome positioning at the 5′ LTR controls viral expression
Regardless of integration position, the latent 5′ LTR typically contains two nucleosomes, Nuc-0
and Nuc-1, at fixed positions [278]. Nuc-1 blocks transcription elongation as it is positioned
just downstream of the TSS. Nuc-1 is displaced upon virus reactivation [278–280]. Nucleo‐
somes can be altered by chromatin remodeling complexes. A third unstable or loosely
positioned nucleosome is located in between nuc-0 and nuc-1 [281] (Figures 2 and 3A).
BCL11B, together with the chromatin remodeling complex NuRD, strongly represses HIV-1
transcription [282]. BCL11B is specifically expressed in T-cells and neurons. Interestingly, the
NuRD complex consists of several proteins with histone deacetylase activities – i.e., HDAC1
and HDAC2 [283,284].
The ATP-dependent chromatin remodeler BAF (SWI/SNF-A) was discovered by our group to
be essential to both the establishment and maintenance of HIV latency (Figure 3). The BAF
complex utilizes energy from ATP to push Nuc-1 from an energetically favorable position
upstream of the TSS to a suboptimal region, downstream of TSS, resulting in a transcriptional
block [281]. siRNA depletion of the BAF complex de-repressed proviral transcription. Fur‐
thermore, in siRNA-mediated BAF knockdown, latency establishment occurred less frequent‐
ly than in the presence of the functional complex. The PIC through LEDGF interacts with INI-1
a subunit of BAF, allowing nucleosomes to be deposited at the provirus, contributing to latency
establishment [118].
4.16. Epigenetic modifications regulate latency
Epigenetic modifications of nucleosomes such as histone-acetylation and -methylation and of
DNA such as DNA-methylation play an important role in regulating the proviral transcription.
Nucleosomes are the basic units of organization of chromatin and consist of a combination of
histone subunits. Histones have an amino acids tail that can be extensively modified. Two
broadly studied modifications that regulate expression effects are histone-acetylation and
histone-methylation
Histone-acetylation by histone acetyl transferases (HATs) induces chromatin loosening, while
histone deacetylases (HDACs) reverse the effect by removing the acetyl group (Figure 3). HATs
such as p300/CREB-binding protein (p300/CBP) and p300/CBP-associated factor (P/CAF) can
be recruited to activate the HIV LTR [158,285]. HDAC1, HDAC2, HDAC3, and HDAC6 repress
HIV [286–289]. Numerous host factors recruit HDACs to the LTR. A negative regulator of P-
TEFb, CTIP2 in cooperation with COUP-TF and Sp1 also recruits HDAC1 and HDAC2 to the
HIV LTR in microglial cells [290,291]. Host factors LSF and YY1 co-operatively bind to the LTR,
where YY1 recruits HDAC1 to deacetylate Nuc-1[207]. CBF-1 and c-Myc also repress HIV
through the recruitment of HDAC1 [208–210].
Methylation of histones by histone methyltransferases (HMT) can act as an activating or
repressing mark depending on the histone tail residue modified (e.g., methylation of lysine 4
on histone 3 (H3K4) is activating whereas H3K9, H3K27, and H4K20 methylation is repressive).
HMTs modify specific histone residues, e.g., EZH2 (H3K27me3), SUV39H1 (H3K9me3), G9a
(H3K9me2), and G9a like protein, GLP (H3K9me2). The repressive methyl groups deposited
Advances in Molecular Retrovirology64
by these HMTs contribute to the maintenance of latency [292–295]. Moreover, EZH2 is
suspected to recruit additional repressive proteins such as HDACs and other HMTs [294].
DNA methylation at CpG dinucleotides represses transcription by disrupting the binding of
transcription activators to their binding sites or indirectly through the binding methyl-CpG
binding proteins (MeCPs). In cell line models of latency, the HIV-1 LTR contains two CpG
islands that are hypermethylated (Figure 3) [296]. Methyl-CpG binding domain protein 2
(MDB2) and HDAC-2 bind to the second CpG island on the HIV LTR and are displaced from
there when cells are treated with cytosine-methylation inihibitor 5-aza-2′deoxycytidine [296].
In memory CD4+ T-cells from long-term aviremic and viremic patients, an increase in HIV
LTR DNA methylation was observed in the aviremic patients [297]. The methylation of the
HIV LTR in long-term non-progressors and elite controllers is increased compared to the LTR
of aviremic patients on cART [298]. In contrast, this difference was not found in the first CpG
island of resting memory CD4+ T-cells from aviremic patients, indicating that the mechanism
by which DNA-methylation regulates latency deserves further exploration.
4.17. Viral and host non-coding RNAs regulate viral expression
Non-coding RNAs exert post transcriptional control on gene expression. Small non-coding
RNAs (<200 nt) and in particular microRNAs (miRNAs) are well established to have regulatory
function. The study of long non-coding RNAs (lncRNA, >200 nt) is an emerging field because
of their epigenetic regulatory potential. Both viral and host miRNAs and lncRNAs affect
replication of HIV-1 [146,299–301].
RNA interference (RNAi) is a post-transcriptional gene silencing mechanism. miRNAs post-
transcriptionally suppress or silence gene expression as part of the RNA-induced silencing
complex (RISC) forming a protein–RNA complex. Pri-miRNAs are generated by RNAPII and
are subsequently processed by microprocessor into pre-miRNAs in the nucleus. Following
export to the cytoplasm, they are cleaved by Dicer and incorporated into RISC. RISC generally
binds in the 3′-untranslated region (3’UTR) of a target mRNA. The bound transcript is
degraded or transcription is impeded depending on the level of homology, resulting in
translational repression. The RNAi affects the infectivity of monocytes and macrophages [302].
Comparisons of productively infected, suppressed, and uninfected patients found difference
in miRNA profiles, but it is very unlikely that the observed effects are due to viral activity
because the number of infected cells is low in elite controllers or under cART [303–305].
Knockdown of Dicer or Drosha, a component of microprocessor, stimulates HIV-1 replication,
indicating that miRNA generally are responsible for suppression of proviral transcription
[299,300]. However, phenotypic effects are hard to interpret due to the pleiotropic side effects
of microprocessor depletion. RNAi affects infectivity by targeting transcripts of key host
factors and viral proteins involved in HIV-1 repression. In resting T-cells, the polycistronic
miRNA cluster miR-17/92 is suppressed by HIV, resulting in PCAF upregulation [299].
Additionally, CycT1 is negatively regulated by miR27b [306]. Moreover, during differentiation
from monocytes to macrophages, expression of miRNA198 and miR27b decreases relieving
suppression of CycT1 [307,308]. In infected cells Tat, and possibly Vpr, inhibit RNAi [309–
311]. In resting, but not activated, CD4+ T-cells a cluster of five miRNAs (miR-28, miR-125b,
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miR-150, miR-223, and miR-382) were found to be upregulated. They all target viral mRNAs
for degradation; therefore, these miRNAs are contributing to latency maintenance [312].
However, further studies are required as results thus far are inconsistent [313–319].
The viral protein Nef is targeted by miR29a which interferes with HIV replication [300,320].
TRIM32 activates HIV-1 expression through the NF-kB pathway and is downregulated by
miRNA-155 [321]. Tat-induced upregulation of miR34a and miR217 inhibits SIRT1 expression,
which in turn results in high abundance of NF-kB, enhancing proviral transcription [322,323].
miRNA-182 has a positive effect on LTR activation by Tat [324]. miR-1236 restricts viral
replication by repressing Vpr (HIV-1)-binding protein expression, VprBP [325].
HIV-1-derived miRNAs (vmiRNAs) were predicted in silico [326]. Applying deep sequenc‐
ing technologies vmiRNAs were observed in cell line model systems of latency [327,328]. The
TAR-derived  miRNA-TAR5p  and  miR-TAR3p  are  asymmetrically  processed  and  both
repress LTR activity [329]. The Nef-derived miR-N367 inhibits viral promotor activity [330].
Nevertheless, relevance of vmiRNAs is debatable as no vmiRNAs were detected in PBMCs
or macrophages of infected patients [331].
lncRNAs can modulate gene expression through different proposed mechanisms: (1) affecting
mRNAs through sequence recognition, (2) recruiting proteins to DNA, (3) blocking host factors
by assuming a secondary structure, (4) functioning as a scaffold for protein complexes. An
anti-sense lncRNA of HIV-1 inhibits viral replication[146]. The non-coding repressor of NFAT
(NRON) inhibits LTR activity in a NFAT-dependent manner [301].
4.18. Stochastic gene expression
The current model of HIV latency proposes that resting memory CD4+ T-cells are deprived of
host factors that are necessary for viral expression. An alternative model proposes that
expression is highly stochastic. Due to fluctuations in chromatin state and availability of the
transcription factors, the latent and productive state co-exist [332]. In support, clonal lines
(containing the same integration) showed binominal distributions of viral expression [333].
Transcriptional bursts of 2–10 mRNA transcripts were estimated to be the source of HIV-1
gene expression [334]. Tat-controlled positive feedback extends the expression reactivation
[335]. The sensitivity to reactivation is also stochastic, as cells derived from patients remained
latent during a first round of activation and were reactivatable in the next round of activation
[83]. Moreover, molecules that increase gene expression fluctuations synergistically enhance
HIV-1 reactivation [336].
5. HIV cure
Mechanistic insight into the complex nature of latent HIV-1 infection provides a rationale for
eradication strategies. Therefore, identification of molecules that inhibit activity of repressors
or potentiate HIV-1 activators alongside with immune system boosting are important objec‐
tives in eradication strategies.
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5.1. Shocking the virus: screening for Latency Reversal Agents (LRAs)
The initial step of LRA discovery is screening drug libraries with cell-line-based models.
Positive hits are evaluated further using primary-cell-based models as they better recapitulate
the nature of latent reservoirs. If effective and not toxic, putative LRAs should undergo
reactivation studies using primary cells derived from HIV-1-positive individuals that are on
cART as well as toxicology studies in animal models, in case of novel molecules. It is advan‐
tageous to include molecules that are already approved drugs in such putative LRAs libraries,
employing them into clinical practice would be time and resources effective. Moreover, in
order to easily diffuse through cell membranes, ideal LRAs are small molecules, with molec‐
ular weight below 900 daltons, although clinical practice shows that most effective compounds
do not exceed 500 daltons [337,338].
The first attempts to reactivate proviral DNA failed, due to the use of agents (e.g., IL-2 or a
monoclonal antibody against CD3 receptor) which resulted in global T-cell activation. Indeed,
viral p24 and plasma HIV-1 RNA levels increased, but the toxicity of such treatment left this
approach useless [339–341]. Therefore, there is a need for more specific agents, which are able
to reactivate proviral transcription without T-cell activation.
5.2. HDAC inhibitors (HDACis)
Histone deacetylase inhibitors (HDACis) are a very promising class of LRAs which include
valporic acid (VPA), Vorinostat (SAHA), Romidepsin, Panobinostat, Givinostat, Droxinostat,
or Entinostat. Some (Vorinostat (SAHA), Romidepsin, Panobinostat) are undergoing clinical
trials [94,342–344].
The focus on HDACis is due to their ability to loosen up the compact chromatin structure at
the latent proviral promoter. Inhibition of HDACs results in an increase of histone acetylation
level by HATs. HDACs 1, 2, and 3 are of particular interest as they considerably contribute to
HIV-1 repression [287]. Fortunately, HDACis are already used in clinical therapies, e.g., VPA
is used in epilepsy and bipolar disorders, Vorinostat and Romidepsin are used to treat
cutaneous T-cell lymphoma (CTCL) while Panabinostat is used in patients with multiple
myeloma. In a very promising study by Archin et al., a single treatment with Vorinostat
resulted in an increase in proviral RNA [345]. Unfortunately, the follow-up study with
additional, multiple-dose rounds of treatment showed that increase on HIV-1 transcription is
neither sustained nor elevated [346]. It is possible that other mechanisms maintaining latency
compensate histone acetylation, in order to restrain proviral transcription. Alternatively such
low concentrations of Vorinostat result in activation of pTEF-b instead of HDAC inhibition
[347]. Since HDACs are involved in general regulation of gene expression; they have pleio‐
tropic effects causing toxicities. Therefore, their use must be strictly controlled and monitored
in order to provide maximal safety [348]. Nevertheless, HDACis are still under much interest.
Especially, finding more specific HDAC inhibitors is very appealing, as current drugs are
inhibiting a wide range of different HDACs, contributing to high toxicity [349].
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5.3. BET inhibitors (BETi’s)
Since BET proteins repress the HIV-1 promoter, it is worth to use their inhibitors in latency
reversal strategies. Treatment with BET protein inhibitor JQ1 reactivates HIV-1 transcription
in Tat-independent fashion [247]. Furthermore, BET inhibitor activity was positively tested in
more relevant primary model system of latency [249]. Unfortunately, JQ-1 is not clinically
available, due to its short half-life.
5.4. HMT inhibitors (HMTis)
Several histone methyltransferases (HMTs) such as EZH2, SUV39H1, and G9a interact with 5′
LTR contributing to maintenance of latency by deposition of repressive methyl groups on
nucleosomal proteins [292–295]. Moreover, EZH2 recruits additional repressive proteins such
as HDACs and other HMTs [294]. Several inhibitors of these proteins were tested in cell lines
or primary cells from HIV-1 positive patients. Among which, Chaetocin (SUV39H1 inhibitor)
and BIX-01294 (G9a inhibitor) were most potent [292,350]. However, high toxicity, due to
pleiotropic effects, makes them unsuitable for clinical practice. Therefore, identification of
novel compounds that are able to inhibit the activity of HMTs is needed.
5.5. DNMT inhibitors (DNMTis)
Inhibition of DNA methyltransferases (DNMTs) with 5-aza-2′ deoxycytidine (aza-CdR or
Decitabine) leads to modest reactivation of latent HIV-1. This activity can be further enhanced
with PKC agonists [351]. However, 5′ LTR methylation in patients material remains contro‐
versial [352]. Thus, further investigation of provirus methylation in vivo is needed.
5.6. Toll-like receptors (TLRs) stimulation
TLRs recently gained more attention, as theirs agonists are strong reactivators of HIV-1 [353–
357]. The main role of these receptors is to activate an immune response against bacterial or
viral infections [358]. Stimulating TLRs (as adjuvants in immunization) as well as opportunistic
bacterial infections elevate plasma HIV-RNA and improve immune function [359–363].
Vaccine adjuvant – CPG 7909 (TLR 9 agonist) is able to decrease plasma HIV-1 RNA via
activation of HIV-specific CD8+ T-cells in peripheral blood [359]. More recently, in SIV-positive
rhesus monkeys undergoing cART were treated with GS-9620, a TLR7 agonist, reversible CD8
cytotoxic T-cells activation alongside with modest CD4 T-cell activation were observed.
Moreover, elevated plasma viremia was observed as well as decrease in HIV-1 DNA in blood,
colon, and lymph nodes. Interestingly, viral load returned back to undetectable levels when
GS-9620 was no longer administrated. More strikingly, when cART was stopped, GS-9620-
treated monkeys had 0.5 log lower viral set-point than untreated, infected animals. Addition‐
ally, in cells isolated from HIV-positive individuals transcription of HIV-1 was observed.
However, some variability between samples was noticed. Clinical trials with the use of this
compound are planned [364,365].
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5.7. Super elongation complex stimulation
Treatment of cell lines and cells isolated from aviremic patients on cART with hexamethylene
bisacetamide (HMBA), an anticancer drug that transiently activates PI3K/Akt pathway, results
in phosphorylation of HEXIM1. P-TEFb is subsequently released and interacts with RNAP II,
resulting in latency reversal [366–368]. Moreover, HMBA provides CDK9 recruitment to the
viral promoter by interaction with SP1, which enhances transcription from proviral DNA.
Furthermore, Klichko et al. showed that treatment with HMBA resulted in a decrease of CD4
receptor expression without affecting transcription of CCR5 and CXCR4 co-receptors [369].
Moreover, HMBA does not trigger activation of T-cells. Studies on P-TEFb’s role in HIV-1
latency indicate that this heterocomplex might be an interesting target for inclusion in “shock
and kill” therapies.
5.8. PKC pathway activation
Another interesting approach is the use of molecules that are able to selectively activate the
protein kinase C (PKC) pathway. PKC pathway agonists trigger nuclear localization of NF-kB,
NFAT, and AP-1 transcription factors. Therefore, PKC agonists are one of the most potent
activators of HIV-1 transcription. Currently, two PKC agonists are being scrutinized clinically:
prostratin and bryostatin, due to their safety and specificity toward HIV-1 reactivation. The
latter is a clinically available drug [370]. Moreover, these two compounds prevent de novo
infections, as they downregulate viral receptor and co-receptors CD4, CCR5 and CXCR4 in
PBMCs [371]. A rather controversial molecule that reactivates HIV-1 transcription via NF-κB
pathway is arsenic trioxide (As2O3). In the Jurkat model system of latency, As2O3 activates NF-
κB leading to HIV-1 replication. Moreover, it synergizes with prostratin, tumor necrosis factor
alpha (TNFα), and VPA [372]. Interestingly, arsenic is already used in clinical practice to treat
acute promyelocytic leukemia (APL). Therefore, it would be interesting to test this compound
in more relevant models of HIV-1 latency such as primary cells infected ex vivo and in cells
derived from aviremic patients.
The use of PKC agonists raises concerns about their safety in a clinical setting. The protein
kinase enzyme family consists of several isoenzymes that play important roles in signal
transduction cascades [373]. As activation of latent HIV-1 is mediated via PKCα and PKCθ,
the identification of more specific agonists of PKCα and PKCθ is needed. Alternatively,
lowering the concentration of a specific agonists might decrease toxicity and contribute to
latency reversal [374].
5.9. JNK/MAPK pathway activation
Studies employing mutagenesis of binding sites for activator protein-1 (AP-1) within the
proviral genome showed that the AP-1 transcription factor is a crucial activator of proviral
transcription, as proviruses with altered AP-1 binding sites were less prone to reactivation
even if treated with a strong activator such as phorbol 12-myristate 13-acetate – PMA [191].
Furthermore, the latent pool of cells infected by virus with deletion in AP-1 sites was bigger,
implicating that AP-1 is necessary for provirus transcription [192]. Heterodimeric protein AP-1
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is formed upon phosphorylation of c-Jun N-terminal kinase (JNK) in JNK/MAPK pathway
[193]. It is well established that activation of TLR signaling induces nuclear localization of NF-
kB and AP-1 mediated via JNK pathway [194,196,376,377].
Virtual screening followed by validation of positive hits in cell line model systems for HIV-1
latency discovered 8-methoxy-6-methylquinolin-4-ol (MMQO) as a specific activator of the
JNK-AP-1 pathway, which is able to reactivate HIV-1 from its latent state. Interestingly,
MMQO inhibits IL-2 and TNFa expression, contributing to maintenance of resting state of
CD4+ T-cells [378]. The recently synthetized panel of inhibitors of farnesyl transferase (FTase)
are able to moderately reactivate HIV-1 transcription via JNK pathway. Interestingly, strong
synergy with other LRAs, such as Vorinostat or TNF-a, was observed for these molecules in
latency reversal [379,380].
5.10. Canonical Wnt signaling pathway activation
Recently, our group showed that treatment with Wnt3A/Rsp (natural stimulators of Wnt
pathway) and lithium (inhibitor of Wnt repressor protein GSK3) leads to latency reversal in
latent cell lines and enhances the latency reversal potential of HDAC inhibitors in CD4+ T
primary cells obtained from patient volunteers when co-treated [381]. This observation shows
a functional role for three LEF1 binding sites in the 5′ LTR contains, which are downstream
targets of the classical Wnt pathway [381,382]. It would be very interesting to find more potent
and selective inducers of Wnt pathway, as lithium exhibits many pleiotropic, toxic effects
[383,384].
5.11. Chromatin loosening
It was discovered by our group that a main player in the establishment and maintenance of
latency is the BAF complex (SWI/SNF-A), which belongs to ATP-dependent chromatin
remodelers’ family. Interestingly, Dykhuizen et al. [378] screened a library of compounds that
would be able to mimic BRG-1 knock out. In their study, they found 20 compounds that were
transcriptionally mimicking BAF complex disruption. We showed that several of those
molecules were able to decrease the frequency of latency establishment and reactivate HIV-1
in cell line and primary cells models of latency [386, in press]. Moreover, they synergize with
other LRAs – SAHA and prostratin. Two most potent inhibitors – caffeic acid phenethyl ester
(CAPE) and pyrimethamine (PYR) did not activate T-cells derived from healthy donors and
cells obtained from aviremic patients. Moreover, PYR is a registered drug used in malaria
treatment. Therefore, these inhibitors are promising molecules to include in eradication
strategies.
5.12. Multifunctional LRAs
In vitro treatment with cocaine leads to increase in HIV- replication in PBMCs as well as
increased viral load in mouse models of HIV infection [387–389]. Interestingly, in ex vivo
infected primary CD4+ cocaine treatment resulted in downregulation of miR125-b expression,
which led to enhanced replication of HIV-1 [314]. In primary human macrophages and myeloid
Advances in Molecular Retrovirology70
cell systems of latency, cocaine increased replication of HIV-1. Cocaine treatment activates NF-
κB and leads to phosphorylation of mitogen- and stress-activated kinase 1 (MSK1). Further‐
more, pMSK1 phosphorylates RELA (p65), a subunit of NF-κB promoting the interaction of
NF-κB with p300 and recruitment of P-TEFb to the proviral 5′ LTR [390]. Moreover, treatment
with cocaine results in histone H3 phosphorylation, thus increasing accessibility of HIV-1
promoter for transcription factors [390]. Therefore, cocaine not only reverses latency via NF-
κB pathway but also causes epigenetic changes on 5′ LTR as well as blocks repressive miRNA.
Oral bacteria secrete short-chain fatty acids (SCFAs) including butyric acid, propionic acid,
isovaleric acid, and isobutyric acid that are capable of HIV-1 and herpesviruses latency reversal
[384,385]. Some of these molecules are known HDACis (e.g. Butyric acid) [393]. Moreover,
SCFAs not only promotes histone acetylation, but also inhibit repressive histone formation
and DNA methylation. Furthermore, they activate P-TEFb resulting in increased elongation
of transcription from 5’ LTR. [345,385,386].
5.13. Immune clearance of reactivated cells – “Kill”
The majority of chronic patients are facing immune exhaustion, characterized by low cytokine
secretion, smaller proliferative capacity, and low cytopathic potential of CD8+ T-cells [394,395].
Therefore, the first line of action would be reviving normal immune activity. Indeed, inhibition
of programmed cell death protein 1 (PD-1) leads to restoration of immune functions in mouse
models of HIV-1 infection [396]. However, these results were obtained in viremic animals.
Nevertheless, an IgG4 antibody targeting PD-1 receptor is undergoing clinical trials to assess
safety, immunotherapeutic activity, and the ability of treatment to reduce pool of latently
infected cells [397].
In so-called “elite controllers”, CD8+ T-cells effectively restrain infection without intervention
of cART, by killing CD4+ T-cells that are actively producing HIV-1 particles [398,399]. The
immune system can be boosted by specific amplification of HIV-1-specific CD8+ T-cells. These
observations again aroused the idea of developing a vaccine. Indeed, rhesus monkeys
vaccinated with CMV vectors resulted in broad cellular immune response to SIV [400–402].
However, safety issues related to the use of such vectors remain to be elucidated. Another
platform being investigated to increase immune response against HIV-1 are Ad26 vectors, as
it was shown that vaccinated rhesus monkeys were protected against infection with SIV as
well as viral loads were lowered after vaccination [403,404].
A very interesting group of immunoglobulins to include in eradication strategies are broadly
neutralizing monoclonal antibodies (mAbs or bNAbs) isolated from chronically infected
patients. New generations of bNAbs exert higher potency and wider range of activity against
many HIV-1 subtypes. It was shown that a combination of bNAbs is potent enough to
transiently suppress viremia in rhesus monkeys as well as to reduce the amount of HIV-1 DNA
in the blood, lymph nodes, and gastrointestinal mucosa [403,405,406].
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6. Future perspectives and challenges
A reservoir of latent HIV is the main obstacle in finding a functional and sterilizing cure.
Several challenges need to be addressed in order to overcome this obstacle. Defining the latent
reservoir is impeded by the rare occurrence of a latent infection in a high background of
defective proviral integration. Although HIV prefers integration in or near transcriptionally
active genes which leaves ample room for variation in chromatin environment and available
host transcription factors. This puts considerable demands on LRAs. LRAs should be effective,
yet specific, without being toxic. As LRAs act via pathways involved in distinct cellular
processes, pleiotropic effects are to be expected. Furthermore, recent studies on material
obtained from HIV-1-positive suppressed patients revealed that currently available LRAs are
not strong enough to reactivate the whole pool of latent proviruses, even after multiple rounds
of stimulation. One of the concerns arising from “shock and kill” therapy is whether putative
LRAs are strong enough to drive virus production to a level at which the immune system will
be able to recognize and destroy HIV-1-producing cells. Indeed, trials aiming at testing HDAC
inhibitors are inconsistent in showing depletion of latently infected cells while showing
increased proviral transcription [407–412]. A complementary strategy would be to use multiple
LRAs in combination to broadly and potentially synergistically reactivate the diversely
integrated latent proviruses. Synergism between LRAs was already identified, e.g., Vorinostat
and Prostratin [84]. Therefore, the quest for identification and characterization of novel
compounds which are able to reactivate HIV-1 transcription as well as identifying combina‐
tions of drugs that can synergize to reverse latency is needed. Currently, no cell model is able
to recapitulate the complexities of latency in vivo. A better system that more closely resembles
the in vivo situation would greatly aid the understanding of molecular mechanisms underlying
latency and the screening of new LRA. Moreover, as HIV-1 persists in a silent state, it contrib‐
utes to a low level of inflammation, which over time leads to immune exhaustion. Furthermore,
depletion of cells harboring latent provirus requires antigen-specific CTLs stimulation [399].
Most likely successful eradication therapies will be based on the combination of LRAs coupled
with boosting HIV-1-specific immune response. A “shock and kill” approach in combination
with immune therapies provides hope for reversing HIV-1 infection.
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